EA201892757A1 - ANTI-BODY THROUGH CYTOSOL AND ITS APPLICATION - Google Patents

ANTI-BODY THROUGH CYTOSOL AND ITS APPLICATION

Info

Publication number
EA201892757A1
EA201892757A1 EA201892757A EA201892757A EA201892757A1 EA 201892757 A1 EA201892757 A1 EA 201892757A1 EA 201892757 A EA201892757 A EA 201892757A EA 201892757 A EA201892757 A EA 201892757A EA 201892757 A1 EA201892757 A1 EA 201892757A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cytosol
exit
variable
antibody
application
Prior art date
Application number
EA201892757A
Other languages
Russian (ru)
Inventor
Ён Сон КИМ
Чи Сун Ким
Чи Ён Пак
Original Assignee
Орум Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орум Терапьютикс Инк. filed Critical Орум Терапьютикс Инк.
Priority claimed from PCT/KR2017/005559 external-priority patent/WO2017204606A1/en
Publication of EA201892757A1 publication Critical patent/EA201892757A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Настоящее раскрытие относится к антителу, проникающему в цитозоль, и его применению и, более конкретно, к идентификации структурного механизма, который индуцирует выход из эндосомы в цитозоль после клеточной интернализации в живых клетках через белок клеточной мембраны, к вариабельному участку легкой цепи и/или вариабельному участку тяжелой цепи, которые основаны на этой идентификации и имеют значительно улучшенную способность к выходу из эндосом в цитозоль, к включающему их антителу, проникающему в цитозоль, к способу его получения и к его применению.The present disclosure relates to an antibody penetrating the cytosol and its use, and more specifically, to identifying the structural mechanism that induces exit from the endosome into the cytosol after cell internalization in living cells through a cell membrane protein, to the variable region of the light chain and / or variable the heavy chain region, which are based on this identification and have a significantly improved ability to exit from the endosomes into the cytosol, to the antibody including them that penetrate the cytosol, to the method for its preparation and to its use.

EA201892757A 2017-05-26 2017-05-26 ANTI-BODY THROUGH CYTOSOL AND ITS APPLICATION EA201892757A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/KR2017/005559 WO2017204606A1 (en) 2016-05-27 2017-05-26 Cytosol-penetrating antibody and use thereof
KR1020170065670A KR20180129514A (en) 2017-05-26 2017-05-26 Cytosol-Penetrating Antibodies and Uses Thereof

Publications (1)

Publication Number Publication Date
EA201892757A1 true EA201892757A1 (en) 2019-07-31

Family

ID=64744205

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892757A EA201892757A1 (en) 2017-05-26 2017-05-26 ANTI-BODY THROUGH CYTOSOL AND ITS APPLICATION

Country Status (2)

Country Link
KR (1) KR20180129514A (en)
EA (1) EA201892757A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102154177B1 (en) * 2019-01-15 2020-09-09 충남대학교 산학협력단 Method for screening enhanced cytosol-penetrating antibody
KR20200088780A (en) * 2019-01-15 2020-07-23 오름테라퓨틱 주식회사 Enhanced cytosol-penetrating antibody
EP4101866A4 (en) * 2020-02-06 2024-04-24 Univ Ajou Ind Academic Coop Found Fusion antibody for presenting antigen-derived t cell antigen epitope or peptide containing same on cell surface, and composition comprising same

Also Published As

Publication number Publication date
KR20180129514A (en) 2018-12-05

Similar Documents

Publication Publication Date Title
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
MX2020001879A (en) Antigen-binding proteins tatrgeting shared antigens.
CY1120471T1 (en) Anti-CD70 antibodies
CL2017000278A1 (en) Bispecific t-cell activating antigen binding molecules
PE20170665A1 (en) HUMANIZED ANTI-TAU ANTIBODIES
CO2018005436A2 (en) Antibodies and antibody fragments for site-specific conjugation
MX2019006043A (en) Prostate specific membrane antigen binding protein.
EA201891709A1 (en) ANTIGENSBINKING PROTEINS, BINDING PD-L1
MX2018009011A (en) Anti-ror1 antibodies and uses thereof.
BR112018068678A2 (en) anti-mica antibodies
PE20140673A1 (en) NEW MODULATORS AND METHODS FOR THEIR USE
MX2018014554A (en) Cytosol-penetrating antibody and use thereof.
PE20171103A1 (en) HETERODIMERIC ANTIBODIES THAT BIND TO CD3 AND CD38
PE20150023A1 (en) ST2 ANTIGEN BINDING PROTEINS
EA201691438A1 (en) ANTIBODY WHICH IS CONNECTED WITH ERBB-2 AND ERBB-3
EA201691795A1 (en) A METHOD FOR IMPROVING THE SOLUBILITY OF PROTEIN AND PEPTIDE AT THE EXPENSE OF USING A BINDING WITH THE FRAGMENT OF IMMUNOGLOBULIN
ES2639026T3 (en) Totally human antibodies specific for CADM1
EA201892774A1 (en) ANTIBODIES
EA201892757A1 (en) ANTI-BODY THROUGH CYTOSOL AND ITS APPLICATION
BR112017013111A2 (en) methods of treating a disorder and treating synovitis, use of an antibody and antibody
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
WO2016023898A3 (en) Intracellular antigen binding
EA201992027A1 (en) WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1
EA202090399A1 (en) SYSTEMS AND METHODS FOR TRAINING IN REAL TIME OF A POLYPEPTIDE SAMPLE FOR ANALYSIS USING MASS SPECTROMETRY
EA201990218A1 (en) ANTIBODIES WITH LOW IMMUNOGENITY AND THEIR APPLICATION